The Delicate CLL Balance: Treatment Benefit vs BTKi Cardio Risk BTK inhibitors offer an evolving treatment paradigm
Recorded Courses
hosted byProjects In Knowledge Inc. (PIK)
hosted byProjects In Knowledge Inc. (PIK)
attend it anywhere online
category
Medicine
Chronic Diseases, Cardiology
price
Free
The Delicate CLL Balance: Treatment Benefit vs BTKi Cardio Risk BTK inhibitors offer an evolving treatment paradigm is organized by Projects In Knowledge Inc. (PIK).
Activity Goal:
The goal of this CME/CE activity is to provide comprehensive and up-to-date information on the best practices in chronic lymphocytic leukemia
Learning Objective(s):
Review available evidence outlining the cardiotoxicity profiles of available BTKis and immunotherapies.
Monitor for and manage arising cardiotoxicities following initiation of BTKis or immunotherapy.
Additional details will be posted as soon as information is available.